Jun. 18 at 11:13 PM
$PHAT 🔥 1. THE MASSIVE REVENUE DISCONNECT
Full-year guidance of
$320M–
$345M is NET revenue! With a 55%–59% Gross-to-Net discount,
$340M net means doctors are writing
$800M+ in gross retail prescriptions right now. At an 80% gross profit margin, this triggers explosive operating leverage. Operating profitability locks in by Q3 2026!
🔒 2. THE LIQUIDITY TRAP IS SPRUNG
Institutions own 88.03% and Insiders own ~5% of the 79.8M shares outstanding. This leaves a tiny, non-existent public retail float of under 7%. Meanwhile, bears have shorted a massive 10.35M shares with a brutal 9.4 Days to Cover. The moment Q2/Q3 numbers confirm this trajectory, a violent, multi-week short squeeze triggers.
🛡️ 3. THE 2040 EVERGREEN PATENT WALL & EU DOMINANCE
The Europe Catalyst: Upon upcoming approval, a single master regulatory dossier will simultaneously secure the entire franchise block across Erosive/Non-Erosive GERD, H. pylori, and the massive EoE immunology pipeline.
